Clinical trials: Randomized Controlled Trial, Human Study
Rheumatoid Arthritis
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid…
- Trial name
- NCT00361335
- Testing
- Golimumab, Methotrexate
- Where
- 72 sites in United States, Argentina and 13 more
- Volunteers
- 643 people
- Sponsor
- Centocor, Inc.
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or…
- Trial name
- NCT07003074
- Testing
- TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
- Where
- 25 sites in China
- Volunteers
- 642 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Healthy Subjects
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
This is first in human (FIH), double-blind, sponsor open, placebo-control trial to examine the safety, tolerability, pharmacokinetics and pharmacodynamics following a single ascending doses of PF-06648671 in healthy subjects.
- Trial name
- NCT02316756
- Testing
- PF-06648671
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Heart Failure
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
- Trial name
- NCT03388593
- Testing
- rhNRG-1
- Where
- 65 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Root Canal Treatment, Post Operative Pain
A First in Human Study to Compare Feasibility of Inertial Cavitation Irrigation to SNI in Root Canal Treatment.
The study design is a single-center 2-arm randomized controlled clinical trial. 10 subjects (teeth) requiring a root canal treatment will be enrolled in 2 groups (5 in each group).
- Trial name
- NCT05374434
- Testing
- Conventional irrigation, Inertial cavitation
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lumendo AG
Hepatitis B
Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine
The main objective of this study was to evaluate the safety and immunogenicity of 10µg/0.5ml and 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside yeast for infants and…
- Trial name
- NCT02152709
- Testing
- 3 dose of 10µg/0.5ml hepatitis B vaccine, 3 dose of 5µg/0.5ml hepatitis B vaccine
- Where
- China
- Volunteers
- 1,537 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Osteoarthritis, Knee
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial of Sprifermin administered intra-articularly in participants with primary osteoarthritis of the knee and Kellgren-Lawrence Grade 2…
- Trial name
- FORWARD (NCT01919164)
- Testing
- Sprifermin
- Where
- 13 sites in United States, Argentina and 6 more
- Volunteers
- 549 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
HIV Infections
PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
The purpose of the study is to determine the safety, tolerability, and plasma pharmacokinetics (i.e., the levels of TMC589337 and TMC589354 circulating in your blood over time) of increasing single oral doses of TMC589337 and…
- Trial name
- NCT00908414
- Testing
- TMC589337 40 mg, TMC589337 100 mg, TMC589337 200 mg
- Where
- Netherlands
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Human African Trypanosomiasis
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
This study is aimed at assessing the tolerability and pharmacokinetic parameters of the fexinidazole in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, fexinidazole shows…
- Trial name
- NCT00982904
- Where
- France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Hepatitis C
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.
- Trial name
- NCT01387958
- Testing
- LCQ908
- Where
- 2 sites in New Zealand
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Virus Infection
A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382
The purpose of this study is to investigate the safety, tolerability and plasma pharmacokinetics (PK) of JNJ-47910382 after increasing single oral doses (taken with food) from 10 mg up to 600 mg or up to the maximum tolerated…
- Trial name
- NCT01482611
- Testing
- JNJ-47910382
- Where
- Germany
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Oxygen Toxicity, Oxidative Stress
Effect of Hydrogen Gas on Hyperbaric Oxygen Toxicity
The goal of this trial is to investigate whether adding a small fraction of hydrogen gas to an oxygen-enriched breathing mixture can reduce pulmonary oxygen toxicity (POT) in healthy and active divers from the Swedish Armed…
- Conditions
- Oxygen Toxicity, Oxidative Stress, Hyperoxia, Hyperbaric Oxygen
- Trial name
- NCT07263399
- Testing
- Inhaled Hydrogen-Enriched Oxygen Gas, Inhaled Nitrogen-Enriched Oxygen Gas
- Where
- 2 sites in Sweden
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Blekinge Institute of Technology
Influenza, Human
Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures
The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination…
- Trial name
- DRIVE (NCT04576377)
- Testing
- FluBlok
- Where
- Hong Kong
- Volunteers
- 977 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Parkinson Disease
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
This study is to evaluate the human tolerance and pharmacokinetics of LY03003.
- Trial name
- NCT04627155
- Testing
- LY03003
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
HER2-positive Breast Cancer
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS , AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection…
- Trial name
- NCT07043725
- Testing
- TQB2102 for injection, Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
- Where
- 78 sites in China
- Volunteers
- 544 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Critical Illness, Septic Shock
Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)
This study will test whether giving human albumin to keep the blood albumin level above 3.5 g/dL, in addition to standard care, improves survival in patients with surgical septic shock.
- Trial name
- ALBUS (NCT07212582)
- Testing
- Human Albumin 20% Solution, Standard Care (in control arm)
- Where
- Thailand
- Volunteers
- 304 people
- Sponsor
- Mahidol University
Healthy Participants
A Study of STAR-0310 in Healthy Adult Participants
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants.
- Trial name
- NCT06782477
- Testing
- STAR-0310
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Astria Therapeutics, Inc.